BIORA THERAPEUTICS INC (PROG) Stock Price, Quote, News and Overview
NASDAQ:PROG - Nasdaq - US74319F1075 - Common Stock
PROG Quote, Performance and Key Statistics
0.8845
-0.03 (-3.47%)
The current stock price of PROG is 0.8845 null. In the past month the price decreased by -25.67%. In the past year, price decreased by -67.48%.
PROG Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CI | THE CIGNA GROUP | 10.97 | 82.08B | ||
| CVS | CVS HEALTH CORP | 11.71 | 79.88B | ||
| LH | LABCORP HOLDINGS INC | 17.15 | 20.84B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.1 | 19.12B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.74 | 13.55B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 148.77 | 12.18B | ||
| DVA | DAVITA INC | 14.99 | 11.68B | ||
| HIMS | HIMS & HERS HEALTH INC | 112 | 10.77B | ||
| CHE | CHEMED CORP | 23.84 | 8.18B | ||
| CRVL | CORVEL CORP | 25.97 | 5.57B | ||
| OPCH | OPTION CARE HEALTH INC | 26.89 | 5.45B | ||
| GH | GUARDANT HEALTH INC | N/A | 5.30B |
Related stock screener links
About PROG
Company Profile
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The company delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.
Company Info
BIORA THERAPEUTICS INC
4330 La Jolla Village Drive, Suite 200
San Diego CALIFORNIA 92122 US
CEO: Harry Stylli
Employees: 124
Company Website: https://www.progenity.com/
Phone: 18552932639.0
BIORA THERAPEUTICS INC / PROG FAQ
What is the stock price of BIORA THERAPEUTICS INC today?
The current stock price of PROG is 0.8845 null. The price decreased by -3.47% in the last trading session.
What is the ticker symbol for BIORA THERAPEUTICS INC stock?
The exchange symbol of BIORA THERAPEUTICS INC is PROG and it is listed on the Nasdaq exchange.
On which exchange is PROG stock listed?
PROG stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIORA THERAPEUTICS INC stock?
7 analysts have analysed PROG and the average price target is 4.08 null. This implies a price increase of 361.28% is expected in the next year compared to the current price of 0.8845. Check the BIORA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIORA THERAPEUTICS INC worth?
BIORA THERAPEUTICS INC (PROG) has a market capitalization of 162.92M null. This makes PROG a Micro Cap stock.
How many employees does BIORA THERAPEUTICS INC have?
BIORA THERAPEUTICS INC (PROG) currently has 124 employees.
What are the support and resistance levels for BIORA THERAPEUTICS INC (PROG) stock?
BIORA THERAPEUTICS INC (PROG) has a support level at 0.84 and a resistance level at 0.96. Check the full technical report for a detailed analysis of PROG support and resistance levels.
Is BIORA THERAPEUTICS INC (PROG) expected to grow?
The Revenue of BIORA THERAPEUTICS INC (PROG) is expected to decline by -100% in the next year. Check the estimates tab for more information on the PROG EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIORA THERAPEUTICS INC (PROG) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PROG, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PROG, evaluating the profitability, health, valuation and growth aspects
- BIORA THERAPEUTICS INC (PROG) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIORA THERAPEUTICS INC (PROG) Sales and EPS estimates to see what analysts future expectations are.
- BIORA THERAPEUTICS INC (PROG) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIORA THERAPEUTICS INC (PROG) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIORA THERAPEUTICS INC (PROG) Stock Chart to make your own analysis
- BIORA THERAPEUTICS INC (PROG) Latest news and press-releases to stay up to date.
Does BIORA THERAPEUTICS INC (PROG) stock pay dividends?
PROG does not pay a dividend.
When does BIORA THERAPEUTICS INC (PROG) report earnings?
BIORA THERAPEUTICS INC (PROG) will report earnings on 2022-08-10.
What is the Price/Earnings (PE) ratio of BIORA THERAPEUTICS INC (PROG)?
BIORA THERAPEUTICS INC (PROG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.23).
PROG Technical Analysis
PROG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PROG. PROG has a bad profitability rating. Also its financial health evaluation is rather negative.
PROG Financial Highlights
Over the last trailing twelve months PROG reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS increased by 68.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -966.06% | ||
| ROA | -227.32% | ||
| ROE | N/A | ||
| Debt/Equity | -1.49 |
PROG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PROG. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 77.59% and a revenue growth -100% for PROG